CL2015003343A1 - Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. - Google Patents

Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.

Info

Publication number
CL2015003343A1
CL2015003343A1 CL2015003343A CL2015003343A CL2015003343A1 CL 2015003343 A1 CL2015003343 A1 CL 2015003343A1 CL 2015003343 A CL2015003343 A CL 2015003343A CL 2015003343 A CL2015003343 A CL 2015003343A CL 2015003343 A1 CL2015003343 A1 CL 2015003343A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
therapeutic agent
hemoglobin
treatment
agent based
Prior art date
Application number
CL2015003343A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Norman Fung Man Wai
Man Kin Wong
Cornelia Wing Yin Man
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of CL2015003343A1 publication Critical patent/CL2015003343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)

Abstract

AGENTE TERAPÉUTICO BASADO EN HEMOGLOBINA MODIFICADA PARA TRATAMIENTO DIRIGIDO AL CÁNCER, E IMAGENOLOGÍA DE DIAGNÓSTICO; COMPOSICIÓN FARMACÉUTICA QUE LO COMPRENDE; Y MÉTODO DE PREPARACIÓN.
CL2015003343A 2013-05-13 2015-11-13 Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. CL2015003343A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361822463P 2013-05-13 2013-05-13
US14/275,885 US9636404B2 (en) 2013-05-13 2014-05-13 Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

Publications (1)

Publication Number Publication Date
CL2015003343A1 true CL2015003343A1 (es) 2016-08-05

Family

ID=51864923

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003343A CL2015003343A1 (es) 2013-05-13 2015-11-13 Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.

Country Status (19)

Country Link
US (2) US9636404B2 (es)
EP (1) EP3001813B1 (es)
JP (1) JP6392855B2 (es)
KR (1) KR102013015B1 (es)
CN (1) CN105407911B (es)
AU (1) AU2014265659B2 (es)
BR (1) BR112015028340A2 (es)
CA (1) CA2911414C (es)
CL (1) CL2015003343A1 (es)
EA (1) EA032164B1 (es)
IL (1) IL242422B (es)
MA (1) MA38571B1 (es)
MX (1) MX362001B (es)
MY (1) MY176175A (es)
PH (1) PH12015502536B1 (es)
SA (1) SA515370134B1 (es)
SG (1) SG11201509042YA (es)
TW (1) TWI610685B (es)
WO (1) WO2014186301A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509042YA (en) * 2013-05-13 2015-12-30 Vision Global Holdings Ltd Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
TR201606102A2 (tr) * 2016-05-10 2016-10-21 Tolgay Tuyan Ilhan Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz
US20230190947A1 (en) * 2016-06-21 2023-06-22 Therapure Biopharma Inc. Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer
US20200237936A1 (en) * 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
CN107153771B (zh) * 2017-05-17 2020-06-30 许昌学院 一种药物分子的同步控制方法及其应用
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
US11576978B2 (en) * 2019-07-19 2023-02-14 Cheer Global Limited Hemoglobin-based therapeutic agents
CN114577557B (zh) * 2020-11-30 2024-06-18 中国科学院大连化学物理研究所 一种基于催化酶激活的靶向交联剂在蛋白分析中的应用
CN114605338B (zh) * 2022-05-11 2022-10-28 深圳厚存纳米药业有限公司 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
CN116068189A (zh) * 2023-04-07 2023-05-05 吉林重明生物科技有限公司 早期癌检测试剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
AU665599B2 (en) * 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
WO1995029925A1 (en) * 1994-04-29 1995-11-09 The Curators Of The University Of Missouri Thioether compounds for use in preparing bifunctional chelating agents for therapeutic radiopharmaceuticals
US5998361A (en) * 1996-10-18 1999-12-07 University Of Maryland At Baltimore Polymerized hemoglobin
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
DE60317303T2 (de) * 2003-04-17 2008-06-19 Ezio Panzeri Hämoglobin-Konjugate
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) * 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
SG11201509042YA (en) * 2013-05-13 2015-12-30 Vision Global Holdings Ltd Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging

Also Published As

Publication number Publication date
MX2015015555A (es) 2016-05-09
MX362001B (es) 2019-01-03
PH12015502536A1 (en) 2016-02-22
IL242422B (en) 2019-02-28
US20140335018A1 (en) 2014-11-13
EA201501065A1 (ru) 2016-04-29
HK1222574A1 (zh) 2017-07-07
WO2014186301A8 (en) 2015-02-05
EA032164B1 (ru) 2019-04-30
CN105407911B (zh) 2020-05-12
AU2014265659B2 (en) 2017-03-30
EP3001813A4 (en) 2017-01-11
EP3001813B1 (en) 2019-03-27
JP6392855B2 (ja) 2018-09-19
KR102013015B1 (ko) 2019-08-21
CN105407911A (zh) 2016-03-16
TW201517921A (zh) 2015-05-16
SG11201509042YA (en) 2015-12-30
CA2911414A1 (en) 2014-11-20
US10322180B2 (en) 2019-06-18
AU2014265659A1 (en) 2015-11-19
US9636404B2 (en) 2017-05-02
PH12015502536B1 (en) 2016-02-22
BR112015028340A2 (pt) 2017-09-19
EP3001813A1 (en) 2016-04-06
SA515370134B1 (ar) 2017-10-18
MA38571B1 (fr) 2018-10-31
JP2016518447A (ja) 2016-06-23
HK1223037A1 (en) 2017-07-21
CA2911414C (en) 2018-09-11
US20170266285A1 (en) 2017-09-21
WO2014186301A1 (en) 2014-11-20
TWI610685B (zh) 2018-01-11
KR20160007536A (ko) 2016-01-20
MA38571A1 (fr) 2017-10-31
MY176175A (en) 2020-07-24

Similar Documents

Publication Publication Date Title
MX2015011753A (es) Metodos para tratar cancer de vegija.
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
BR112016022345A2 (pt) terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
MX378273B (es) Compuestos activos hacia bromodominios.
PT4000608T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CR20120202A (es) Métodos y composiciones para tratar cáncer
CR20160289A (es) Compuestos de inhibidor de autotaxina
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EP3581182A4 (en) DRUG COMBINATION FOR THE TREATMENT OF PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer